首页> 中文期刊> 《中国医药导刊》 >甘露聚糖肽胶囊预防慢性阻塞性肺疾病急性加重的疗效观察

甘露聚糖肽胶囊预防慢性阻塞性肺疾病急性加重的疗效观察

         

摘要

目的:观察甘露聚糖肽胶囊预防慢性阻塞性肺病急性加重的疗效.方法:将120例慢性阻塞性肺病急性加重期(AECOPD)住院患者按随机数表随机分为治疗组和对照组,各60例.两组在常规治疗(抗生素+舒利迭)基础上,治疗组加用甘露聚糖肽胶囊,对照组加用泛福舒胶囊(细菌溶解产物),观察两组治疗12月内COPD急性加重次数与每次发作抗生素使用量;测定免疫学指标:CD3+、CD4+、CD8+、CD4+/CD8+(比值)、IgA、NK细胞.结果:治疗组在COPD急性加重次数及急性加重期抗生素使用量两项临床指标均优于泛福舒;甘露聚糖肽明显增加CD3+、CD4+及CD4+/CD8+含量,降低CD8+含量,与对照组间存在显著性差异(P<0.05).结论:甘露聚糖肽胶囊可提高患者免疫功能,能有效减少AECOPD患者的发作次数,减少抗生素应用.%Objective: To observe the clinical efficacy of mannatide capsules in prevention acute exacerbation of chronic obstructive pulmonary disease patients.Methods:120 patients with COPD were divided into treatment group (n=60)and control group(n=60) randomly. On the base of conventional treatment(antibiotics plus Seretide),The patients in treatment group were administrated with mannatide capsules,those in control group were administrated with broncho-vaxom. Then the difference in the times of acute exacerbation,antibiotic consumption,CD3+,CD4+,CD8+,CD4+/CD8+,IgA,NK cells after treatment during 12monthes were observed.Results:The treatment group was better than the control group in the terms of the times of acute exacerbation and antibiotic consumption, The treatment group significantly increased the content of CD3+,CD4+and CD4+/CD8+,decrease the content of CD8+ and there is significant difference (P < 0.05) between the two group.Conclution:Mannatide capsules can enhance the immune function in patients with COPD,reduce the attack of AECOPD and the duration of antibiotics use, improve the patient's clinical symptoms.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号